Immutep Limited
ASX:IMM.AX
Overview | Financials
Company Name | Immutep Limited |
Symbol | IMM.AX |
Currency | AUD |
Price | 0.355 |
Market Cap | 515,676,550 |
Dividend Yield | 0% |
52-week-range | 0.23 - 0.485 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Marc Voigt |
Website | https://www.immutep.com |
An error occurred while fetching data.
About Immutep Limited
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD